Point72 Europe London LLP Grows Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Point72 Europe London LLP increased its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 13.8% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 546,035 shares of the life sciences company’s stock after buying an additional 66,400 shares during the quarter. Integra LifeSciences comprises approximately 1.3% of Point72 Europe London LLP’s portfolio, making the stock its 20th biggest position. Point72 Europe London LLP’s holdings in Integra LifeSciences were worth $15,911,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Blue Trust Inc. lifted its holdings in Integra LifeSciences by 100.5% in the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 444 shares during the period. CWM LLC raised its holdings in Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 425 shares during the period. Valley National Advisers Inc. purchased a new position in Integra LifeSciences during the first quarter valued at $63,000. Canada Pension Plan Investment Board bought a new stake in Integra LifeSciences during the second quarter valued at about $114,000. Finally, Northwest Investment Counselors LLC purchased a new stake in Integra LifeSciences in the first quarter worth about $143,000. Institutional investors own 84.78% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Citigroup cut their price objective on Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating for the company in a research note on Thursday, August 22nd. BTIG Research reduced their price objective on shares of Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating for the company in a research note on Wednesday, August 28th. Morgan Stanley lifted their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research note on Monday, July 15th. JMP Securities dropped their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, July 30th. Finally, Truist Financial decreased their price target on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating on the stock in a report on Tuesday, July 30th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.63.

Integra LifeSciences Stock Up 1.9 %

Shares of IART stock opened at $17.88 on Wednesday. The stock has a market cap of $1.39 billion, a P/E ratio of 35.76, a PEG ratio of 0.60 and a beta of 1.10. The company’s fifty day simple moving average is $22.16 and its two-hundred day simple moving average is $27.53. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. Integra LifeSciences Holdings Co. has a 52 week low of $16.96 and a 52 week high of $45.42.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The company had revenue of $418.20 million during the quarter, compared to analyst estimates of $413.07 million. During the same period in the prior year, the company earned $0.71 earnings per share. The firm’s revenue was up 9.7% on a year-over-year basis. Analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.